Satellos initiated with an Outperform at Leerink

Leerink initiated coverage of Satellos (MSLE) with an Outperform rating and $20 price target The firm believes Satellos represents a differentiated early clinical-stage opportunity in Duchenne muscular dystrophy/DMD, underpinned by a novel regeneration-based mechanism and supported by encouraging early data that give Leerink more confidence in the biology. While the program remains high risk given the limited clinical validation to date, the firm sees a favorable risk/reward driven by a clear upcoming catalyst path, including continued updates from the TRAILHEAD study in adult DMD patients and the potentially pivotal Phase 2 BASECAMP study, which will read out in Q4 2026.